As previously reported, Canaccord initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $89 price target Apogee is a “significant player” in the immunology and inflammatory disease, or I&I, space whose lead drug, APG777, is in Phase 2 study for the treatment of moderate-to-severe atopic dermatitis, or AD, more commonly known as eczema, the analyst tells investors. The AD market is largely dominated by topical therapies, yet the clinical benefit of topical agents falls short, notes the analyst, who believes APG777, with a familiar mechanism and differentiated dose scheduling, has the “potential to dominate in the young and growing market for biologics in AD” and offers “blockbuster potential,” the analyst added.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics initiated with a Buy at Canaccord
- Apogee Therapeutics Highlights Pipeline Progress and Financials
- Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028
- Apogee Therapeutics, Inc. (APGE) Q3 Earnings Cheat Sheet
- Apogee Therapeutics price target raised to $100 from $81 at BTIG